SG11201907638QA - Proteins binding cd33, nkg2d and cd16 - Google Patents

Proteins binding cd33, nkg2d and cd16

Info

Publication number
SG11201907638QA
SG11201907638QA SG11201907638QA SG11201907638QA SG11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA
Authority
SG
Singapore
Prior art keywords
international
lebanon
lucent
pct
drive
Prior art date
Application number
SG11201907638QA
Other languages
English (en)
Inventor
Gregory Chang
Ann Cheung
William Haney
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11201907638QA publication Critical patent/SG11201907638QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201907638QA 2017-02-20 2018-02-20 Proteins binding cd33, nkg2d and cd16 SG11201907638QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461145P 2017-02-20 2017-02-20
PCT/US2018/018768 WO2018152516A1 (fr) 2017-02-20 2018-02-20 Protéines de liaison à cd33, nkg2d et cd16

Publications (1)

Publication Number Publication Date
SG11201907638QA true SG11201907638QA (en) 2019-09-27

Family

ID=63169992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907638QA SG11201907638QA (en) 2017-02-20 2018-02-20 Proteins binding cd33, nkg2d and cd16

Country Status (12)

Country Link
US (1) US20210130471A1 (fr)
EP (1) EP3583131A4 (fr)
JP (2) JP2020510646A (fr)
KR (1) KR20190120775A (fr)
CN (1) CN110573530A (fr)
AU (1) AU2018220734A1 (fr)
BR (1) BR112019017277A2 (fr)
CA (1) CA3054078A1 (fr)
IL (1) IL268790A (fr)
MA (1) MA47508A (fr)
SG (1) SG11201907638QA (fr)
WO (1) WO2018152516A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
CN113121697B (zh) * 2019-12-31 2023-06-09 周易 Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用
CN115197330B (zh) * 2021-04-14 2023-04-28 广州百暨基因科技有限公司 同时靶向cll1和cd33的嵌合抗原受体及其应用
CN116948029A (zh) * 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260153B2 (en) * 2000-03-24 2006-08-17 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
ES2483942T5 (es) * 2007-12-14 2017-02-06 Novo Nordisk A/S Anticuerpos contra NKG2D humano y usos de los mismos
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2332994A1 (fr) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
AU2014232501C1 (en) * 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
WO2014198748A1 (fr) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer
JP6919118B2 (ja) * 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
EP2985294A1 (fr) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible
EP2990416B1 (fr) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Récepteur d'antigène chimérique universel exprimant des cellules immunitaires pour le ciblage de divers antigènes multiples et son procédé de fabrication et son utilisation pour le traitement du cancer, des infections et des troubles auto-immuns
EP3029137B1 (fr) * 2014-12-06 2019-01-02 GEMoaB Monoclonals GmbH Cellules souches pluri-ou multipotentes génétiquement modifiées et leurs utilisations
IL255884B2 (en) * 2015-06-10 2024-05-01 Immunitybio Inc Modified NK-92 cells for cancer treatment
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
AU2018219887A1 (en) * 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer

Also Published As

Publication number Publication date
RU2019129174A3 (fr) 2021-07-02
MA47508A (fr) 2021-03-17
KR20190120775A (ko) 2019-10-24
RU2019129174A (ru) 2021-03-22
BR112019017277A2 (pt) 2020-04-14
WO2018152516A1 (fr) 2018-08-23
CN110573530A (zh) 2019-12-13
JP2020510646A (ja) 2020-04-09
CA3054078A1 (fr) 2018-08-23
US20210130471A1 (en) 2021-05-06
EP3583131A1 (fr) 2019-12-25
AU2018220734A1 (en) 2019-09-12
IL268790A (en) 2019-10-31
JP2023052214A (ja) 2023-04-11
EP3583131A4 (fr) 2021-03-17

Similar Documents

Publication Publication Date Title
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201907271PA (en) Proteins binding psma, nkg2d and cd16
SG11201907648XA (en) Proteins binding gd2, nkg2d and cd16
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
CA3015496A1 (fr) Commande vocale d'un systeme de lecture multimedia
SG11201808014SA (en) Compositions, devices, and methods for cell separation
SG11201907645PA (en) Proteins binding cd123, nkg2d and cd16
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201900501RA (en) Cannabis composition
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201908456VA (en) Linker units and molecular constructs comprising same